Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling
HER-2 overexpression is a major mechanism involved in endocrine-resistant breast cancer, which has very limited treatment options. Zoledronic acid (ZA) is a drug in the bisphosphonate group used to treat osteoporosis. ZA was reported to exhibit activity in various cancers, with higher efficacy assoc...
Main Authors: | Patthamapon Adchariyasakulchai, Nithidol Sakunrangsit, Sarun Chokyakorn, Chayanin Suksanong, Wannarasmi Ketchart |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332224000234 |
Similar Items
-
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
by: Susanne Crocamo, et al.
Published: (2022-12-01) -
Polyarthritis following infusion of zoledronic acid: a case study
by: T. Campbell
Published: (2023-07-01) -
Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
by: Aya Alsalih, et al.
Published: (2021-07-01) -
Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis
by: Ping Wu, et al.
Published: (2024-02-01) -
Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis
by: Yang Tao, et al.
Published: (2011-08-01)